Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.

Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22.


Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.

Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R.

Mol Cancer Ther. 2019 May;18(5):1001-1011. doi: 10.1158/1535-7163.MCT-17-1038. Epub 2019 Mar 29.


Breast Cancer Mortality in Older and Younger Patients in California.

Tao L, Schwab RB, San Miguel Y, Gomez SL, Canchola AJ, Gago-Dominguez M, Komenaka IK, Murphy JD, Molinolo AA, Martinez ME.

Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):303-310. doi: 10.1158/1055-9965.EPI-18-0353. Epub 2018 Oct 17.


Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.


Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer.

D Antonio M, Weghorn D, D Antonio-Chronowska A, Coulet F, Olson KM, DeBoever C, Drees F, Arias A, Alakus H, Richardson AL, Schwab RB, Farley EK, Sunyaev SR, Frazer KA.

Nat Commun. 2017 Sep 5;8(1):436. doi: 10.1038/s41467-017-00100-x.


Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.

Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R.

Clin Cancer Res. 2016 Nov 15;22(22):5497-5505. doi: 10.1158/1078-0432.CCR-16-0318. Epub 2016 May 16.


Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.


Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R.

Oncotarget. 2016 Mar 1;7(9):9707-17. doi: 10.18632/oncotarget.7110.


Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution.

Komenaka IK, Nodora JN, Madlensky L, Winton LM, Heberer MA, Schwab RB, Weitzel JN, Martinez ME.

J Community Genet. 2016 Jul;7(3):177-83. doi: 10.1007/s12687-015-0257-x. Epub 2015 Dec 21.


Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.

Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R.

Oncotarget. 2015 Oct 20;6(32):32602-9. doi: 10.18632/oncotarget.5289.


A window-of-opportunity biomarker study of etodolac in resectable breast cancer.

Schwab RB, Kato S, Crain B, Pu M, Messer K, Weidner N, Blair SL, Wallace AM, Carson DA, Parker BA.

Cancer Med. 2015 Oct;4(10):1583-8. doi: 10.1002/cam4.512. Epub 2015 Aug 15.


Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.

Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R.

J Oncol Pract. 2015 Nov;11(6):442-9. doi: 10.1200/JOP.2015.004127. Epub 2015 Aug 4.


Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis.

Mausbach BT, Schwab RB, Irwin SA.

Breast Cancer Res Treat. 2015 Jul;152(2):239-46. doi: 10.1007/s10549-015-3471-7. Epub 2015 Jun 16. Review.


Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.

Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Cell Cycle. 2015;14(11):1730-7. doi: 10.1080/15384101.2015.1033596.


On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.

Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Mol Cancer Ther. 2015 Jun;14(6):1488-94. doi: 10.1158/1535-7163.MCT-14-1061. Epub 2015 Apr 7.


Cyclin alterations in diverse cancers: Outcome and co-amplification network.

Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Oncotarget. 2015 Feb 20;6(5):3033-42.


Breast cancer in a RAD51D mutation carrier: case report and review of the literature.

Baker JL, Schwab RB, Wallace AM, Madlensky L.

Clin Breast Cancer. 2015 Feb;15(1):e71-5. doi: 10.1016/j.clbc.2014.08.005. Epub 2014 Sep 23. Review. No abstract available.


Correction: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 Jul 26;6(7):53. doi: 10.1186/s13073-014-0053-y. eCollection 2014. No abstract available.


Occult primary, version 3.2014.

Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Jul;12(7):969-74.


Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 May 29;6(5):43. doi: 10.1186/gm559. eCollection 2014.


Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R.

Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5.


Reproductive risk factors and breast cancer subtypes: a review of the literature.

Anderson KN, Schwab RB, Martinez ME.

Breast Cancer Res Treat. 2014 Feb;144(1):1-10. doi: 10.1007/s10549-014-2852-7. Epub 2014 Jan 30. Review.


Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.

Harismendy O, Schwab RB, Alakus H, Yost SE, Matsui H, Hasteh F, Wallace AM, Park HL, Madlensky L, Parker B, Carpenter PM, Jepsen K, Anton-Culver H, Frazer KA.

Breast Cancer Res. 2013 Dec 10;15(6):R115. doi: 10.1186/bcr3584.


Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T.

PLoS One. 2013 Jun 27;8(6):e67258. doi: 10.1371/journal.pone.0067258. Print 2013.


Mutascope: sensitive detection of somatic mutations from deep amplicon sequencing.

Yost SE, Alakus H, Matsui H, Schwab RB, Jepsen K, Frazer KA, Harismendy O.

Bioinformatics. 2013 Aug 1;29(15):1908-9. doi: 10.1093/bioinformatics/btt305. Epub 2013 May 27.


Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer.

Barrett CL, Schwab RB, Jung H, Crain B, Goff DJ, Jamieson CH, Thistlethwaite PA, Harismendy O, Carson DA, Frazer KA.

PLoS One. 2013;8(3):e58714. doi: 10.1371/journal.pone.0058714. Epub 2013 Mar 20.


Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens.

Yost SE, Smith EN, Schwab RB, Bao L, Jung H, Wang X, Voest E, Pierce JP, Messer K, Parker BA, Harismendy O, Frazer KA.

Nucleic Acids Res. 2012 Aug;40(14):e107. Epub 2012 Apr 6.


Efficacy and pharmacogenomic biomarkers in breast cancer.

Paul AK, Schwab RB.

Biomark Med. 2012 Apr;6(2):211-21. doi: 10.2217/BMM.12.7. Review.


Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.

Harismendy O, Schwab RB, Bao L, Olson J, Rozenzhak S, Kotsopoulos SK, Pond S, Crain B, Chee MS, Messer K, Link DR, Frazer KA.

Genome Biol. 2011 Dec 20;12(12):R124. doi: 10.1186/gb-2011-12-12-r124.


Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia.

Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC, Rosenbach MD, Corr M, Schwab RB, Carson DA.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7479-84. doi: 10.1073/pnas.1002890107. Epub 2010 Apr 5.


Analysis of the association of proteins with membranes.

Okamoto T, Schwab RB, Scherer PE, Lisanti MP.

Curr Protoc Cell Biol. 2001 May;Chapter 5:Unit 5.4. doi: 10.1002/0471143030.cb0101s05.


Some epidemiologic aspects of psychosomatic medicine.

Schwab JJ, Bell RA, Warheit GJ, Schwab RB, Traven ND.

Int J Psychiatry Med. 1978-1979;9(2):147-58.


Social psychiatry and psychosomatics.

Schwab JJ, Schwab RB.

Psychosomatics. 1975;16(4):151-4. No abstract available.


Psychosomatic medicine and the contemporary social scene.

Schwab JJ, McGinnis NH, Norris LB, Schwab RB.

Am J Psychiatry. 1970 May;126(11):1632-42. No abstract available.


Supplemental Content

Loading ...
Support Center